NuCana (NCNA) vs PharmaCyte Biotech (PMCB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NuCana is the larger company by market cap ($4.7 million vs $4.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NCNA | PMCB |
|---|---|---|
| Share price | $1.13 | $0.3974 |
| Market cap | $4.70M | $4.27M |
| 1-day change | -0.88% | -2.02% |
| EPS (TTM) | $0.00 | $-2.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.40 | $1.51 |
| 52-week low | $0.948 | $0.3339 |
| Distance from 52-week high | -82.34% | -73.68% |
| Average volume | 123.99K | 205.72K |
| Shares outstanding | 4.16M | 10.74M |
| Employees | 10 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About NuCana
NCNA stock →NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines.
Healthcare · Biotechnology · 10 employees
About PharmaCyte Biotech
PMCB stock →PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer.
Healthcare · Biotechnology · 2 employees
NCNA vs PMCB FAQ
Which is bigger, NuCana or PharmaCyte Biotech?
NuCana (NCNA) is larger, with a market capitalization of $4.70M compared with $4.27M for PharmaCyte Biotech (PMCB).
Are NuCana and PharmaCyte Biotech in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.